323 related articles for article (PubMed ID: 9613720)
1. Current status of selegiline as a neuroprotective agent in Parkinson's disease.
Olanow CW; Mytilineou C; Tatton W
Mov Disord; 1998; 13 Suppl 1():55-8. PubMed ID: 9613720
[No Abstract] [Full Text] [Related]
2. Moderate Parkinson's disease. Strategies for maximizing treatment.
Silverstein PM
Postgrad Med; 1996 Jan; 99(1):52-4, 61-3, 67-8, passim. PubMed ID: 8539210
[TBL] [Abstract][Full Text] [Related]
3. [Drug therapy of Parkinson's disease].
Myllylä V
Duodecim; 1997; 113(18):1827-34. PubMed ID: 10892076
[No Abstract] [Full Text] [Related]
4. Selegiline in Parkinson's disease.
Calne DB
BMJ; 1995 Dec; 311(7020):1583-4. PubMed ID: 8555790
[No Abstract] [Full Text] [Related]
5. Deprenyl in Parkinson's disease.
Korczyn AD; Nisipeanu P
Ann Neurol; 1996 Aug; 40(2):268-9. PubMed ID: 8773617
[No Abstract] [Full Text] [Related]
6. Selegiline and mortality in subjects with Parkinson's disease: a longitudinal community study.
Ben-Shlomo Y; Lees A;
Neurology; 2001 Jul; 57(2):369; author reply 369-70. PubMed ID: 11480425
[No Abstract] [Full Text] [Related]
7. DATATOP-study: significance of its results in the treatment of Parkinson's disease.
Schneider E
J Neural Transm Suppl; 1995; 46():391-7. PubMed ID: 8821074
[TBL] [Abstract][Full Text] [Related]
8. The relevance of preclinical studies for the treatment of Parkinson's disease.
Gerlach M; Foley P; Riederer P
J Neurol; 2003 Feb; 250 Suppl 1():I31-4. PubMed ID: 12761633
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
Chen JJ; Swope DM; Dashtipour K
Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
[TBL] [Abstract][Full Text] [Related]
10. Neuroprotective agents in Parkinson's disease: clinical evidence and caveats.
Hälbig TD; Tse W; Olanow CW
Neurol Clin; 2004 Oct; 22(3 Suppl):S1-S17. PubMed ID: 15501359
[No Abstract] [Full Text] [Related]
11. Recent advances in Parkinson's disease.
Vécsei L
Ideggyogy Sz; 2002 Nov; 55(11-12):406-7. PubMed ID: 12632802
[No Abstract] [Full Text] [Related]
12. Deprenyl and levodopa and Parkinson's disease progression.
Fowler JS; Fazzini E; Volkow ND
Ann Neurol; 1996 Aug; 40(2):267-8. PubMed ID: 8773616
[No Abstract] [Full Text] [Related]
13. Neuroprotective therapy for Parkinson's disease.
Koller WC
Exp Neurol; 1997 Mar; 144(1):24-8. PubMed ID: 9126147
[TBL] [Abstract][Full Text] [Related]
14. Rasagiline as a therapy for Parkinson's disease (PD).
Hermanowicz N
Am J Geriatr Pharmacother; 2007 Jun; 5(2):174-5; author reply 175-6. PubMed ID: 17719520
[No Abstract] [Full Text] [Related]
15. Deprenyl's neuroprotective action remains unresolved.
van Hilten JJ; Bloem BR; Klaassen AA
Ann Neurol; 1996 Aug; 40(2):266-7. PubMed ID: 8773615
[No Abstract] [Full Text] [Related]
16. Selegiline: a second look. Six years later: too risky in Parkinson's disease.
Prescrire Int; 2002 Aug; 11(60):108-11. PubMed ID: 12199263
[TBL] [Abstract][Full Text] [Related]
17. Hypersexuality and paraphilia induced by selegiline in Parkinson's disease: report of 2 cases.
Shapiro MA; Chang YL; Munson SK; Okun MS; Fernandez HH
Parkinsonism Relat Disord; 2006 Sep; 12(6):392-5. PubMed ID: 16730214
[TBL] [Abstract][Full Text] [Related]
18. [Levodopa+selegiline combination and increase of risk of mortality in the treatment of Parkinson disease].
Dubois B; Montastruc JL
Rev Neurol (Paris); 1996 Feb; 152(2):103-5. PubMed ID: 8761616
[No Abstract] [Full Text] [Related]
19. Practical importance of neuroprotection in Parkinson's disease.
Riederer P; Gille G; Müller T; Przuntek H; Reichmann H; Riess O; Schwartz A; Schwarz J; Vogt T
J Neurol; 2002 Oct; 249 Suppl 3():III/53-6. PubMed ID: 12522574
[TBL] [Abstract][Full Text] [Related]
20. Treatment challenges in early stage Parkinson's disease.
Tetrud J
Neurol Clin; 2004 Oct; 22(3 Suppl):S19-33. PubMed ID: 15501364
[No Abstract] [Full Text] [Related]
[Next] [New Search]
